TITLE

Homicidal Ideation Causally Related to Therapeutic Medications

AUTHOR(S)
Marks, Donald H.; Breggin, Peter R.; Braslow, Derek
PUB. DATE
November 2008
SOURCE
Ethical Human Psychology & Psychiatry;Fall2008, Vol. 10 Issue 3, p134
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Five patients with hepatitis C (HCV), three of whom were treated with peginterferon alfa-2 (IFN) and two who were not treated with IFN, developed homicidal ideation (HI) during a 4-year period. Following accepted rules for determining causation, there appeared to be a causal relatedness between IFN use and the development of homicidal ideation for those patients taking IFN. None of these patients attempted a homicidal act while on treatment with IFN, nor in the follow-up period after treatment. The incidence of HI while treated with IFN in our patient population is estimated to be less than 1%. The ability of prescription medication to cause homicidal ideation is reviewed, and legal implications are discussed.
ACCESSION #
36410848

 

Related Articles

  • Interferon's Effects on Depression. Breindl, Anette // BioWorld Today;6/11/2012, Vol. 23 Issue 112, Special section p2 

    The article reports on a study which investigated the role of interferon-gamma treatment in depression among hepatitis C patients.

  • Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin. Kleppinger, Erika L.; Ragan, Addison P. // American Journal of Health-System Pharmacy;3/1/2009, Vol. 66 Issue 5, p465 

    Purpose. The case of a patient with hepatitis C who developed elevated hepatic transaminase levels associated with the use of interferon alfacon-1 and ribavirin is described. Summary. A 55-year-old Caucasian man arrived at a hepatitis C clinic to discuss alternative treatment options for his...

  • Mineralization of Acephate, a Recalcitrant Organophosphate Insecticide Is Initiated by a Pseudomonad in Environmental Samples. Pinjari, Aleem Basha; Novikov, Boris; Rezenom, Yohannes H.; Russell, David H.; Wales, Melinda E.; Siddavattam, Dayananda // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    An aerobic bacterium capable of breaking down the pesticide acephate (O,S-dimethyl acetyl phosphoramidothioic acid) was isolated from activated sludge collected from a pesticide manufacturing facility. A phylogenetic tree based on the 16 S rRNA gene sequence determined that the isolate lies...

  • Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. Davis, Gary L.; Esteban-Mur, Rafael; Rustgi, Vinod; Hoefs, John; Gordon, Stuart C.; Trepo, Christian; Shiffman, Mitchell L.; Zeuzem, Stefan; Craxi, Antonio; Ling, Mei-Hsiu; Albrecht, Janice // New England Journal of Medicine;11/19/98, Vol. 339 Issue 21, p1493 

    Background: Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for...

  • The effects and underlying mechanism of interferon therapy on body weight and body composition. Alam, Ibrar; Ullah, Niamat; Alam, Iftikhar; Ali, Ijaz // Pakistan Journal of Pharmaceutical Sciences;Nov2013, Vol. 26 Issue 6, p1251 

    Body weight changes in HCV patients on interferon therapy are well documented. However, the underlying mechanism involved in these changes is poorly understood and rarely reported. The main objectives of this review are to 1) discuss changes in body weight and other compartments of body...

  • Surgical Treatment for Hepatocellular Carcinoma Detected After Successful Interferon Therapy. Shoji Kubo; Hiromu Tanaka; Shigekazu Takemura; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Taichi Shuto; Kazuhiro Hirohashi // Surgery Today;Apr2007, Vol. 37 Issue 4, p285 

    AbstractPurpose  Interferon therapy suppresses the development of hepatocellular carcinoma (HCC) and tumor recurrence after a resection of HCC in patients with chronic hepatitis C. However, the value of a liver resection and which method is best for the treatment of HCC detected...

  • Interferon α-2b/ribavirin.  // Reactions Weekly;10/3/2009, Issue 1272, p20 

    The article describes the case of a 64-year-old woman with chronic hepatitis C who developed a widespread eruption after receiving interferon α-2b and ribavirin once weekly. The said eruption affected her face, arms and trunk. When the patient began treatment with topical dexamethasone, her...

  • Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. Andriulli, A.; Iacobellis, A.; Valvano, M.; Spirito, F.; Ippolito, A.; Bossa, F.; Terracciano, F.; Fontana, R.; Niro, G. // Digestive Diseases & Sciences;May2013, Vol. 58 Issue 5, p1371 

    Background: Given the significant side-effects and healthcare costs associated with telaprevir- or boceprevir-combination therapy, identifying patients likely to respond to dual therapy peg-interferon (Peg-IFN)/ribavirin is highly desirable. Since the perception of how large the pool of patients...

  • Boceprevir/peginterferon-α-2a/ribavirin: Metabolic encephalopathy in an elderly patient: case report.  // Reactions Weekly;Nov2013, Issue 1477, p10 

    The article presents a case study of an elderly woman with hepatitis C who developed metabolic encephalopathy while being treated with the drugs peginterferon-α-2a (Pegasys), ribavirin, and boceprevir.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics